Related to Studies Suggest that When It Comes to Drug Development Success, Size Matters

• SuppreMol Secures €15.5M to Advance Protein Therapeutics for Autoimmune Diseases
  
• Axcan to Buy Pancreatic Enzyme Product Firm Eurand for $583M
  
• BMS Negotiates Rights to Oncolys BioPharma's HIV Candidate
  
• GSK and McGill University Partner to Develop Treatment for Cystic Fibrosis
  
• Evotec Expands Screening Library with Addition of 110,000 ChemBridge Compounds
  
• FDA Requests More Data from Existing Trials with Protalix’ Gaucher Disease Drug
  
• Bristol-Myers Squibb Taps WuXi for Stability Testing
  
• Amgen Grants Tesaro Rights to Small Molecule Candidates for Cancer Treatment
  
• Pfizer to Attack Lysosomal Storage Diseases with Zacharon’s Small Molecule Approach
  
• Alnylam Extends RNAi Alliance with UBC and AlCana Technologies
  
• CellMed to Leverage Scarab Genomics’ Clean Genome E. coli Technology
  
• Proteostasis Therapeutics Licenses Protein Clearance Targets and Compounds from Harvard
  
• Beactica to Apply SPR-Based Drug Discovery Platform to Janssen Targets
  
• Oncothyreon Expects to Net $37.4M to Advance Cancer Pipeline
  
• FDA Expands Sutent Label to Include Pancreatic Neuroendocrine Tumors
  
• Elan Makes $20M Investment in Proteostasis as Part of Drug Discovery Partnership for Neurodegenerative Diseases
  
• Evotec Pays €10.25M for Galapagos’ Compound-Management Business
  
• Plexxikon and Roche Report Positive Data from Phase III BRAF Mutation Melanoma Study
  
• Lonza Eyes CHF 10M Expansion of Singapore Biopharmaceutical Development Facility
  
• Ambit Scores $30M to Advance Kinase Inhibitor Pipeline